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N-(cyanomethyl)glycine methyl ester and sodium azide 
as a key step. This building block was then employed in 
the solid phase synthesis of a tetramer peptoid. The linear 
tetramer was subjected to macrocyclization using PyBOP 
to obtain a cyclic peptoid with (1H-tetrazol-5-yl)methyl 
pendants in good yield.
Abstract A solid phase synthesis of a cyclic peptoid 
bearing (1H-tetrazol-5-yl)methyl as N-substituent has been 
developed employing the monomer approach. The requisite 
monomeric Nosyl-protected N-(1-trityl-1H-tetrazol-5-yl)
methyl substituted glycine was accessed by a conveni-
ent synthesis involving Click reaction of Nosyl-protected 
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Introduction
Peptoids, (poly-N-substituted glycines) (Simon et al. 1992; 
Culf and Ouellette 2010) represent a class of α-peptide 
mimics where in the backbone side chains attached to 
α-carbon are “moved” to the backbone amide nitrogen 
atom. In addition to N-substituted versions of the pro-
teinogenic side chains, various primary amines can be 
directly incorporated as their N-substituents (Miller et  al. 
1994; Timothy et  al. 2003). They can be generated using 
a straight forward, modular synthesis and offer great prom-
ise for biological applications because of the incorporation 
of a wide variety of functionalities. The enhanced proteo-
lytic stability (Udugamasooriya et  al. 2008; Wender et  al. 
2000; and; Kwon and Kodadek 2007) and increased cellu-
lar permeability (Zukermann et al. 1992a, b; Yu et al. 2005) 
relative to α-peptides are the important attributes that hold 
potential for their use as tools to study biomolecular inter-
actions and for therapeutic applications (Hara et al. 2006; 
Xiao et al. 2007; and; Patch and Barron 2002; Patch et al. 
2004). A number of short oligomeric peptoids (<8-mers) 
have been found to bind therapeutically relevant proteins, 
act as antagonists, inhibitors or activators (Goodson et  al. 
1999; Ng et  al. 1999; Zuckermann et  al. 1992a, b; Heiz-
mann et  al. 1999; Marti´nez et  al. 2002; Thompson et  al. 
2003). Similar to peptides, cyclization of peptoids has been 
an efficient strategy to enhance conformational order result-
ing in improved biostability, biological activity and unique 
supramolecular architectures (Shin et al. 2007; Shah et al. 
2008; Maulucci et  al. 2008; Huang et  al. 2013). Cyclic 
peptoids have also found applications in metal binding 
(Izzo et  al. 2013; Cola et  al. 2014), phase transfer cataly-
sis (Schettini et al. 2014) and cation transport (Cola et al. 
2009).
On the other hand, heterocycles play vital role in drug 
discovery as underscored by their structural rigidity, com-
plexity and diversity of the library of heterocycle contain-
ing small molecule drugs (Abell 2002; El-Dahshan et  al. 
2011; Cerminara et  al. 2012; Yu et  al. 2002). Moreover, 
heterocycles can increase the aqueous solubility of oligom-
ers when compared to all carbon units (Combs and Lokey 
2007; Aquino et  al. 2012). The insertion of heterocycles 
in to peptoids is of significant interest which is expected 
to favor the conformational constraints in the peptoid oli-
gomer (Aditya and Kodadek 2012). The heterocyclic 
motives may confer stabilized three-dimensional structure 
on the resulting hybrid molecules leading to improvements 
in ligand binding or inhibition, there by improved pharma-
cokinetic properties (Aditya and Kodadek 2012). The side 
chain heterocyclic nitrogen atoms are significant by their 
ability to chelate metals and exhibit unique spectroscopic 
properties. In line with this strategy, heterocycles such as 
oxazole, thiazole, pyridazine have been incorporated into 
peptoid backbone (Aditya and Kodadek 2012). Also the 
incorporation of a 1,5-disubstituted-1,2,3-triazole (Pokor-
ski et  al. 2007) or a 1,3,5-triazine (Lee et  al. 2010) unit 
into the peptoid has resulted in improved conformational 
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stability of those peptoids. In addition, several nitrogen 
containing heterocycles such as imidazoles, quinolines, 
indoles, pyridines and pyrazines have been incorporated as 
N-side chains in peptoids (Burkoth et al. 2003).
Tetrazoles are an important class of heterocycles with 
wide range of applications as drugs in pharmaceuticals and 
as carboxylic acid surrogates for biological studies (Singh 
et al. 1980; Myznikov et al. 2007; Meanwell 2011; and; Biot 
et al. 2004). They are also known as cis amide bond surro-
gates with increased resistance towards metabolic degrada-
tion pathways (Zabrocki et al. 1988, 1992). Click chemistry 
{[3 + 2] cycloaddition between azide and alkyne/nitrile} 
based triazole or tetrazole formation is often employed to 
bridge two molecular fragments to increase the confor-
mational order and to improve the bioactivity (Holub and 
Kirshenbaum 2010, 2007, 2006; Jang et al. 2005; Sidonie 
et al. 2012). Tetrazole-containing analogues of amino acids 
and peptides exhibit biological activity including antibacte-
rial (Stone et  al. 2004), antiviral (Johansson et  al. 2003), 
antiarrhythmic activity (Wu et al. 2006) and also serves as 
inhibitors of nitric oxide biosynthesis (Penke et al. 2006). 
It is also well documented in the literature that the deriva-
tives of tetrazoles are useful as stimulators of growth hor-
mone release and are explored as metallo-protease inhibi-
tors (Popova and Trifonov 2015). In this report, we present 
a design for the synthesis of a (1H-tetrazol-5-yl)methyl 
tethered cyclic peptoid tetramer by a solution phase head to 
tail macrocyclization approach. The requisite tetramer was 
accessed via solid phase monomer approach using Nosyl-
protected N-(1-trityl-1H-tetrazol-5-yl)methyl substituted 
glycine. The building block can be obtained by a conveni-
ent synthesis involving Click reaction of Nosyl-protected 
N-(cyanomethyl)glycine methyl ester and sodium azide as 
a key step.
Results and Discussion
We started with the preparation of monomeric Nosyl-pro-
tected N-(1-trityl-1H-tetrazol-5-yl)methyl substituted gly-
cine (Nosyl = o-nitrobenzenesulfonyl) (Scheme  1). Firstly, 
the alkylation of Nosyl-protected glycine methyl ester with 
bromoacetonitrile was carried out. Various bases such as 
NaH,  K2CO3,  Cs2CO3 and  Na2CO3 were screened in dif-
ferent solvents including DMF, THF, acetone and  CH3CN. 
The  K2CO3as a base in acetone solvent at room temperature 
was found to be an optimized condition for the N-alkylation 
on Nosyl protected glycine methyl ester with 95% yield.
Thus obtained alkylated compound was subjected to 
Click chemistry employing  NaN3 in DMF under reflux con-
dition for 6 h (Scheme 1). After completion of the reaction 
(as monitored by TLC), the reaction mixture was cooled 
and treated with water and ethyl acetate (EtOAc). A simple 
work up provided the desired Nosyl-protected N-(1H-tetra-
zol-5-yl)methyl substituted glycine methyl ester. In the next 
step, the acidic tetrazole-NH is protected with trityl group 
to avoid any undesired side reactions during solid phase 
peptide synthesis (SPPS). The ester hydrolysis resulted in 
the desired monomer Nosyl-protected N-(1-trityl-1H-tetra-
zol-5-yl)methyl substituted glycine (80%) 6 to be employed 
in SPPS of target N-(1H-tetrazol-5-yl)methyl peptoid.
With the monomeric building block in hand, SPPS of 
(1-trityl-1H-tetrazol-5-yl)methyl peptoid tetramer was 
undertaken (Scheme  2). The 2-chlorotrityl resin was 
Scheme 1  Preparation of Nosyl-protected N-(1-trityl-1H-tetrazol-5-yl)methyl substituted glycine monomer
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chosen as the support. The chlorotrityl resin was treated 
with the N-(1-trityl-1H-tetrazol-5-yl)methyl substituted 
glycine monomer in the presence of diisopropylethylamine 
(DIEA)/DCM for 6 h to establish an ester linkage. The first 
attachment was confirmed by weight gain experiments.
After the successful attachment of first monomer, the 
Nosyl group was deprotected using 2-mercaptoethanol and 
1,8-diazabicyclo[5.4.0]undec-7-ene(DBU) in DMF solvent. 
Thus, 2-mercaptoethanol (10 equiv.) and DBU (5 equiv.) in 
DMF were added to the resin and the mixture was allowed 
to swirl for 20 min. The same process was repeated again 
to avail the complete Nosyl deprotection. Next, the resin 
attached monomer was then coupled with the monomer 
6 usingO-(benzotriazol-1-yl)-1,1,3,3-tetramethyluroni-
umhexafluorophosphate (HBTU; 4 equiv.)/1-hydroxy-
benzotriazole (HOBt; 4 equiv.)/DIEA (6 equiv.) in DMF 
for 60 min. The formation of dimer was confirmed by the 
cleavage of small portion of resin for mass analysis. In the 
next stage, deprotection of nosyl group and the subsequent 
coupling with peptoid monomer 6 was repeated to achieve 
the desired peptoid tetramer 11. After deprotection of 
Nosyl group, the (1-trityl-1H-tetrazol-5-yl)methyl tethered 
peptoid tetramer was released from 2-chlorotrityl resin. The 
resin cleavage was performed with trifluoroethanol (TFE)/
AcOH/DCM (1:1:3) solution for 2 h at room temperature. 
The resin was filtered and washed with the DCM thor-
oughly. The combined filtrate was evaporated to dryness 
at reduced pressure to afford the free peptoid tetramer as a 
solid in 81% yield. The product was purified by semi-Prep 
RP-HPLC chromatography and characterized by MALDI-
TOF mass spectrometry (see supporting information).
Cyclic peptides and cyclic peptidomimetics are of great 
interest in drug discovery and chemical biology. Relative to 
their linear counterparts, they have desirable features such 
as protein binding property (Roxin and Zheng 2012). In the 
next part of the study, the cyclization of thus obtained (1-tri-
tyl-1H-tetrazol-5-yl)methyl tethered peptoid tetramer was 
carried out. Various coupling reagents were examined for 
the effective cyclization of (1-trityl-1H-tetrazol-5-yl)methyl 
tethered peptoid tetramer to obtain the 18 membered cyclic 
Scheme 2  Solid phase synthesis of (1-trityl-1H-tetrazol-5-yl)methyl peptoid tetramer
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peptoid (Table  1). In general, macrocyclization is a yield 
limiting step which has to be performed under high dilution 
conditions. A suitable coupling reagent can render an effi-
cient cyclization. Thus, to affect the head to tail cyclization 
of the linear peptoid several coupling reagents such as ben-
zotriazole-1-yloxytris(pyrrolidino)-phosphonium hexafluo-
rophosphate (PyBOP), bromotris(pyrrolidino)phosphonium 
hexafluorophosphate (PyBrOP), 2-(6-chloro-1H-benzotria-
zol-1-yl)-1,1,3,3-tetramethylaminium hexafluorophosphate 
(HCTU), HBTU and N,N’-diisopropylcarbodiimide (DIC) 
were examined (Table 1).
All the coupling reagents (Table  1, entries b–e) could 
generate the desired cyclic product albeit with low yield 
and significant by products. However, cyclization using 
PyBOP (Table 1; entry a) resulted in a better yield (60%) of 
the cyclic peptoid tetramer as compared to other reagents. 
In a typical cyclization, the linear peptoid (100 mg) was dis-
solved in DMF (140 ml). PyBOP (40.48 mg, 1.2 eq), DIEA 
(33.87  μl, 3  eq) was added to the reaction mixture and 
allowed to stir for 6–8 h at room temperature (Scheme 3). 
The formation of undesired products may be due to the 
ring strain has been reported previously for cyclization of 
tetramer and pentamer peptoids (Davies 2003). It can be 
noted that, PyBOP is especially useful for the cyclization of 
hindered amino acids and has been successfully employed 
in some of the previously reported macrocyclizations (Shin 
et al. 2007; Shah et al. 2008).
After completion of the peptoid cyclization, the trityl 
groups were deprotected using 10% TFA in DCM for 3 h. 
The reaction mixture was filtered and washed with DCM. 
Evaporation of TFA followed by lyophilization provided 
the desired cyclic peptoid derivative as a gummy solid in 
60% yield. HRMS analysis of the crude product confirmed 
the formation of the cyclic peptoid. The RP-HPLC analy-
sis of crude reaction mixture had two peaks with retention 
times at 13.67 (corresponding to the cyclic peptoid 15) 
and at 18.60 (unprotected linear N-methyltetrazole pep-
toid tetramer 13). The crude cyclic peptoid was then dis-
solved in acetonitrile : water (1 : 1) and purified by semi-
Prep RP-HPLC chromatography (conditions: 10–80% ACN 
in 90 min, 232 nm, 10 ml flow). The pure product 15 was 
obtained about 52% yield and characterized by HRMS 
analysis.
Experimental
Materials and Methods
All solvents, reagents and glycine were purchased from 
sigma aldrich company and were used as received. All 
reaction mixtures were stirred magnetically and were moni-
tored by thin-layer chromatography (TLC) using precoated 
silica gel 60F-254 (0.25) plates. Spots were visualized with 
UV light and ninhydrin. Solvents were evaporated under 
Table 1  Optimization of macrocyclization using coupling reagents
a Yield of the crude product
Entry Condition Yield (%)a
a PyBOP/DIEA/DMF 60
b PyBrOP/DIEA/DMF 18
c HCTU/DIEA/DMF 25
d HBTU/DIEA/DMF 15
e DIC/DIEA/DMF 12
Scheme 3  Head to tail macrocyclization of (1-trityl-1H-tetrazol-5-yl)methyl tethered peptoid tetramer using PyBOP and detritylation
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reduced pressure at 40 °C. Column chromatography was 
carried out using silica gel (100–200 mesh). 1H NMR spec-
tra were recorded on a Bruker AMX 300 MHz with  CDCl3 
as an internal standard. Mass spectra were recorded using 
high resolution mass spectrometer (HRMS) and electron 
spray ionization mass spectrometry (ESI–MS) of mass 
spectrometer. The splitting patterns of proton are s (sin-
glet), d (doublet), t (triplet) m (multiplet) and br s (broad 
singlet). The synthetic purity was determined by using ana-
lytical RP-HPLC, column: Agilent eclipse XDB-C-18, pore 
size −5  μm, diameter × length = 4.6 × 150  mm (method: 
Water-MeCN; MeCN 30% −100% in 30  min; gradient 
0.1% TFA; λ = 254 nm, flow: 0.5 ml/min).
General Procedure for the Preparation of Methyl 
2-(N-(cyanomethyl)-2-nitrophenylsulfonamido)Acetate 
(3)
To a solution of nosyl protected glycine methyl ester (1.0 
equiv.) in acetone was added  K2CO3 (2.2 equiv.) and 2-bro-
moacetonitrile (1.1 equiv.). The reaction mixture was 
allowed to stir at room temperature till completion (as mon-
itored by TLC). Solvent was evaporated in vacuo and the 
residue was dissolved in EtOAc (3 × 10  ml). The organic 
layer was washed with 5% HCl (20  ml), water (20  ml), 
brine solution (10  ml) and dried over anhydrous  Na2SO4 
and the organic layer was evaporated to obtain the product.
General Procedure for the Preparation 
of Methyl 2-(N-((1H-tetrazol-5-yl)
methyl)-2-nitrophenylsulfonamido)Acetate (4)
To a solution of methyl 2-(N-(cyanomethyl)-2-nitrophenyl-
sulfonamido) acetate (1.0 equiv.) in IPA:  H2O (1:1), sodium 
azide (2.5 equiv.), sodium ascarbonate (0.1 equiv.) and cop-
per sulphate (0.76 equiv.) were added. The reaction mixture 
was stirred at 80 °C for 6  h (as monitored by TLC). The 
reaction mixture was then diluted with water (3 × 10  ml) 
and ethyl acetate (3 × 15 ml). The organic layer was sepa-
rated and washed with 5% HCl (20 ml), water (15 ml) brine 
solution (10  ml) and dried over anhydrous  Na2SO4, fol-
lowed by concentration to obtain the product.
General Procedure for the Preparation of Methyl 
2-(2-nitro-N-((1-trityl-1H-tetrazol-5-yl)methyl)
phenylsulfonamido)Acetate (5)
Methyl 2-(N-((1H-tetrazol-5-yl)methyl)-2-nitrophenylsul-
fonamido)acetate (1.0 equiv.) was dissolved in DCM,  Et3N 
(1.2 equiv.) and trityl chloride (1.5 equiv.) were added at 
0 °C. The reaction mixture was stirred at rt about 2 h. Sol-
vent was evaporated in vacuo and the residue was dissolved 
in EtOAc (3 × 10 ml). The organic layer was washed with 
water (20 ml), brine solution (10 ml) and dried over anhy-
drous  Na2SO4 and the organic layer was evaporated to 
obtain the product about 80% yield.
Synthesis of Peptoid: The Tetramer Sequence 
was Carried Out by Following this General Procedure:
Nosyl Deprotection
β-Mercaptoethanol (10 equiv.) and DBU (5.0 equiv.) in 
DMF were added to the resin bound monomer (1.0 equiv.) 
and the mixture was allowed to swirl for 20 min. The same 
process was repeated again to ensure the complete depro-
tection of nosyl group.
Step 1: The chlorotrityl resin bound halogen was added 
to the solution of tetrazole substituted glycine monomer 
(1.0 equiv.), DIEA (5.0 equiv.) in dry DCM. Agitate the 
mixture with a shaker for 5  min, then add 1.5 equiv. of 
respective to the monomer and DIPEA. Agitate the mixture 
vigorously for 45 min, washed with DMF (5 × 2.0 mL).
Step 2: To the resin bound tetrazole substituted glycine 
amine was added to the solution of tetrazole substituted 
glycine monomer, HBTU (4.0 equiv)/HOBt (4.0 equiv)/
DIEA (6.0 equiv) in DMF, and this was allowed to react 
for 60  min. After completion, the resin was drained and 
washed with DMF (6 × 2.0 ml).
The monomer coupling cycle was repeated until the 
desired tetramer length was achieved.
Cleavage Protocol
The peptoid product was cleaved from the resin by employ-
ing TFE/AcOH/DCM (1:1:3) solution for 2  h at room 
temperature with gentle stirring. The cleavage solution 
was filtered to remove the resin beads, and the filtrate was 
evaporated under a stream of nitrogen, resuspende in 1:1 
acetonitrile/water and then lyophilized twice. The crude 
percent yield was calculated on the basis of the weight of 
the lyophilized product plus the appropriate counter ions.
General Procedure for Head to Tail Cyclization 
and Trityl Group Deprotection (15)
A solution of (1-trityl-1H-tetrazol-5-yl)methyl tethered 
peptoid tetramer (1.0 equiv.) in DMF and PyBOP (1.2 
equiv.) was added DIEA (3.0 equiv.) to the reaction mixture 
and allowed to stir for 6–8 h at room temperature. The reac-
tion vessel was flushed with nitrogen and sealed to exclude 
air. After completion of the reaction, 10% TFA in DCM 
was added and stirred for 3  h. The reaction mixture was 
diluted with 50% ACN in  H2O to quench the reaction. The 
diluted sample was analyzed by HPLC.
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Characterization Data
Methyl 2‑(N‑(cyanomethyl)‑2‑nitrophenylsulfonamido)
Acetate [3]
Yield: (86%), 1H NMR (300 MHz,  CDCl3): δ 3.59 (s, 3H), 
4.24 (s, 2H), 4.54 (s, 2H), 8.17 (t, J = 5.7  Hz, 2H), 8.41 
(d, J = 5.4 Hz, 2H) ppm; ESI-MS: m/z [M + Na]+calcd for 
 C11H11N3NaO6S: 313.04; found: 337.13.
Methyl 2‑(N‑((1H‑tetrazol‑5‑yl)
methyl)‑2‑nitrophenylsulfonamido)acetate [4]
Yield: (82%), 1H NMR (300 MHz,  CDCl3): δ 3.58 (s, 3H), 
4.19 (s, 2H), 4.93 (s, 2H), 7.79–8.11 (m, 4H) ppm; ESI-
MS: m/z [M + Na]+calcd for  C11H12N6NaO6S: 356.05; 
found: 380.11.
2‑(2‑Nitro‑N‑((1‑trityl‑1H‑tetrazol‑5‑yl)methyl)
phenylsulfonamido)Acetic Acid [6]
Yield: (75%), 1H NMR (300 MHz,  CDCl3): δ 4.15 (s, 2H), 
4.28 (s, 2H), 7.21–7.80 (m, 19H), 8.50 (br s, 1H) ppm.
Conclusion
We have developed an efficient strategy for the synthesis 
of peptoid monomer Nosyl-protected N-(1H-tetrazol-5-yl)
methyl substituted glycine. Furthermore, a convenient solid 
phase synthesis of novel (1-trityl-1H-tetrazol-5-yl)methyl 
peptoid tetramer and its cyclization in solution phase to 
the corresponding cyclomer has been achieved. The pep-
toid tetramer was synthesized using solid phase monomer 
strategy and the coupling reagent PyBOP could achieve 
the head to tail cyclization of linear tetramer into the cyclic 
peptoid in moderate yield. The formation of the linear and 
cyclic peptoid tetramer was confirmed by HRMS analysis. 
The pure cyclic (1H-tetrazol-5-yl)methyl peptoid molecule 
was isolated after semi-prep RP-HPLC purification.
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